Genpharmasec Ltd (GENPHARMA) is currently trading at 1.08 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Genpharmasec Limited, established in 1992, is primarily engaged in pharmaceutical activities and trading in equity shares, initially focusing on chemicals and pigments manufacturing. The company pivoted in 2018 towards pharmaceuticals and ventured into securities trading, marking a strategic shift in operations. In 2019, Genpharmasec entered the medical device segment, securing distribution rights for Abbott's diagnostic equipment, a move aimed at diversification. Recently, the company enhanced profitability by importing Abbott cartridges directly, cementing its position in the diagnostic equipment distribution sector. With consistent efforts to expand beyond single partnerships, Genpharmasec is actively seeking growth opportunities to avoid sales stagnation.

Over the past 52 weeks, Genpharmasec Ltd has traded between a low of ₹0.75 and a high of ₹1.62. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Genpharmasec Ltd has a market capitalization of approximately 60.91. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Genpharmasec Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 44.14 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 60.91 Cr, Genpharmasec Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Genpharmasec Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Genpharmasec Ltd is 44.14. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Genpharmasec reported consolidated profit after tax of Rs 1.03 crore for the quarter ended September 30, 2026. It had reported a consolidated loss after tax of Rs 1.18 crore in the quarter ended September 30, 2025. Total tax expense in the latest quarter was Rs 55.02 lakh.

Genpharmasec has approved the sale of its entire equity stake in Clinigenome India. Clinigenome India was a wholly owned subsidiary when the board approved the proposal on November 3, 2026. It will cease to be a wholly owned subsidiary only after completion.

Genpharmasec Limited said its Board approved the sale of its entire equity stake in Clinigenome India Private Limited. The company identified Clinigenome India as a non-material subsidiary, but did not state a separate strategic reason for the proposed sale.

The 'Biopharma Shakti' scheme is the key announcement, with a ₹10,000 crore outlay over five years aimed at boosting domestic biopharmaceutical manufacturing, research, and clinical trials.